Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders (Tables)

9 Months Ended

Sep. 30, 2022

Earnings Per Share [Abstract]

Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders

The following table sets forth the computation of the basic and diluted net loss per share attributable to our common shareholders for the three and nine months ended September 30, 2022 and 2021, respectively (in thousands, except share and per share amounts):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2022			2021			2022			2021
Net loss attributable to Adaptive Biotechnologies Corporation	$	(45,281	)	$	(55,903	)	$	(160,063	)	$	(145,846	)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted		142,928,654			140,833,564			142,334,342			140,060,379
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted	$	(0.32	)	$	(0.40	)	$	(1.12	)	$	(1.04	)

Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share

The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to our common shareholders for the three and nine months ended September 30, 2022 and 2021, respectively, as they had an anti-dilutive effect:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Stock options outstanding		13,996,403		12,901,028		13,984,427		13,205,328
Nonvested restricted stock units outstanding		5,486,711		795,469		4,490,170		572,194
Maximum nonvested market-based restricted stock units outstanding eligible to be earned		494,234		—		381,990		—
Common stock warrant outstanding		—		—		—		11,458
Total		19,977,348		13,696,497		18,856,587		13,788,980